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SUMMARY  
Polycomb repressive complexes PRC1 and PRC2 regulate expression of genes 
involved in proliferation and development. In mouse early embryos, however, canonical 
PRC1 localizes to paternal pericentric heterochromatin (pat-PCH), where it represses 
transcription of major satellite repeats. In contrast, maternal PCH (mat-PCH) is enriched 
for H3 lysine 9 tri-methylation (H3K9me3) and Hp1β. How PRC1 is targeted to pat-PCH 
yet excluded from mat-PCH has remained elusive. Here, we identify a PRC1 targeting 
mechanism that relies on Cbx2 and Hp1β. Cbx2 directs catalytically active PRC1 to 
PCH via its chromodomain (CDCbx2) and neighboring AT-hook (ATCbx2) binding to 
H3K27me3 and AT-rich major satellites, respectively. CDCbx2 prevents ATCbx2 from 
interacting with DNA at PCH marked by H3K9me3 and Hp1β. Loss-of-function studies 
show that Hp1β and not H3K9me3 prevents PRC1 targeting to mat-PCH. Our findings 
indicate that CDCbx2 and ATCbx2 separated by a short linker function together to integrate 
H3K9me3/HP1 and H3K27me3 states. 
 
INTRODUCTION 
 In higher eukaryotes, various chromatin pathways evolved to organize the 
genome into different compartments comprising of euchromatin, facultative and 
constitutive heterochromatin and to regulate gene expression (Campos and Reinberg, 
2009; Fodor et al., 2010). Within each pathway, a plethora of chromatin modifying 
enzymes and associated proteins collaborate to define distinct chromatin states. 
Constitutive heterochromatin is generally found at repetitive sequences, for example 
those flanking centromeres in a variety of organisms ranging from 
Schizosaccharomyces pombe to human. In mice, pericentromeric heterochromatin 
(PCH) domains are comprised of 234 bp long AT-rich DNA sequences, called major 
satellites, organized in tandem arrays of several Mb length (Vissel and Choo, 1989). 
PCH is characterized by DNA methylation as well as Suv39h-mediated H3K9me3 that is 
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bound by HP1 proteins which in turn recruit the Suv4-20h histone lysine 
methyltransferases (HMTs) to catalyze H4K20me2/3 (Lachner et al., 2001; Li et al., 
1992; Peters et al., 2001; Schotta et al., 2004). Impairment of constitutive 
heterochromatin is associated with increased major satellite transcription, nuclear 
organization defects and improper chromosome condensation and segregation (Hahn et 
al., 2013; Peters et al., 2001).  
Facultative heterochromatin is generally enriched for Polycomb group (PcG) 
proteins that robustly modify chromatin and suppress non-lineage specific gene 
expression, thereby safeguarding developmental potency in embryonic and tissue-
specific stem cells, during cellular differentiation and even in the mammalian germ line 
(Aloia et al., 2013; Posfai et al., 2012; Yokobayashi et al., 2013). In mammals, PcG 
proteins function in two main families of complexes, referred to as PRC1 and PRC2, 
that catalyze mono-ubiquitination of histone H2A on lysine 119 (H2AK119ub1) and tri-
methylation of histone H3 on lysine 27 (H3K27me3) respectively (Beisel and Paro, 
2011). How PRCs are targeted to chromatin has been subject of intense research. For 
years, PRC2-mediated H3K27me3 was thought to recruit PRC1 via the CD of Cbx 
proteins (Cao et al., 2002). More recently, however, variant PRC1 (vPRC1) complexes 
lacking Cbx subunits were shown to be targeted in ESCs to unmethylated CpG-island 
containing promoters via the CXXC DNA-binding motif of Kdm2b, independently of 
H3K27me3. Moreover, catalytic activity of vPRC1 directed PRC2 recruitment, resulting 
in H3K27me3 deposition (Blackledge et al., 2014; Cooper et al., 2014; Kalb et al., 
2014).  
Intriguingly, deletion of the two Suv39h HMTs in mouse embryonic stem cells 
(Suv39h double null (dn) ESCs) or the three DNA methyltransferases (TKO ESCs) 
results in accumulation of H3K27me3 and/or H2AK119ub1 at PCH (Cooper et al., 2014; 
Peters et al., 2003; Saksouk et al., 2014) demonstrating plasticity between PcG 
complexes and components of the classical constitutive heterochromatin pathway. High 
resolution immunofluorescence (IF) and protein composition analyses of PCH in TKO 
ESCs suggest a possible direct role for DNA methylation in preventing vPRC1 
recruitment to PCH, presumably by blocking Kdm2b binding to DNA (Cooper et al., 
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2014; Saksouk et al., 2014). On the other hand, PRC2 recruitment seems to be 
constrained by components in the Suv39h pathway other than those involved in DNA 
methylation (Cooper et al., 2014; Peters et al., 2003). Then again, Saksouk et al. (2014) 
identified Bend3 as a methylation-sensitive DNA-binding protein that is required for 
H3K27me3 accumulation at PCH in Suv39h dn ESCs, likely in Dnmt TKO ESCs and 
possibly in early mouse embryos. Currently, it is unclear to what extent such molecular 
interplay observed in ESCs is relevant for mouse development.  
Mouse early embryos represent a unique situation in which mat-PCH and pat-
PCH, although present in the same cellular environment, are formatted in distinct 
manners that reflect different chromatin reprogramming histories during gametogenesis 
(Gill et al., 2012; Puschendorf et al., 2008). Whereas mat-PCH in zygotes is 
characterized by classical  heterochromatin features, components of a maternally 
provided canonical PRC1 complex called “matPRC1” like Cbx2, Bmi1, Phc2 and Rnf2 
label pat-PCH where they suppress transcription of major satellite transcripts 
(Puschendorf et al., 2008). Furthermore, matPRC1 associates with mat-PCH in 
Suv39h2m-z+ zygotes which lacks H3K9me3. Thus, matPRC1 functions as a repressive 
back-up mechanism of the Suv39/HP1 pathway.  
We also demonstrated that matPRC1 targeting to pat-PCH is unaffected in Ezh2 
m-z+ embryos, suggesting a possible involvement of vPRC1 (Puschendorf et al., 2008). 
Then again, H3K27me3 is established normally at pat-PCH in zygotes deficient for Rnf2 
arguing against a role for vPRC1 in PRC2 recruitment to pat-PCH. Finally, despite 
major changes in euchromatic DNA methylation patterns, paternal PCH remains DNA 
methylated during early pre-implantation development (Arand et al., 2015; Inoue et al., 
2011) pointing to different mechanisms of PRC1 recruitment to pat-PCH in early 
embryos versus ESCs.   
Here we unravel the molecular mechanism underlying targeting of matPRC1 to 
pat-PCH and its exclusion from mat-PCH. We show that Cbx2 directly targets 
catalytically active matPRC1 to pat-PCH via its CD and an AT-hook DNA binding 
domain that bind to H3K27me3-modified nucleosomes and AT-rich major satellites. Our 
studies suggest that CDCbx2 and ATCbx2 connected by a short linker function as one 
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reader module that integrates the H3K9me3/HP1 and H3K27me3 chromatin states for 
DNA binding by the AT-hook. Increasing the affinity of CDCbx2 for H3K9me3 by a single 
amino acid change enables Cbx2 binding to H3K9me3/Hp1 marked PCH. Likewise, 
loss of maternal Hp1 results in strong matPRC1 localization at mat-PCH, despite the 
presence of H3K9me3. We conclude that Hp1 and not H3K9me3 prevents matPRC1 
from binding mat-PCH. These data assign an important function to Cbx2 and Hp1 in 
specifying target selectivity of matPRC1 during early embryonic development. 
 
RESULTS 
Canonical PRC1 marks constitutive heterochromatin in mouse early embryos 
Several “canonical” matPRC1 components label pat-PCH which in zygotes is 
organized in a spherical configuration around nucleolar-precursor bodies (NPBs) 
(Puschendorf et al., 2008). Besides these cPRC1 members, transcripts for various 
vPRC1 subunits are also maternally provided to the early embryo (Figure S1A) (Park et 
al., 2013). To investigate whether such vPRC1 members localize to pat-PCH in late 
zygotes, we performed IF analysis for Rybp using a specific antibody (Figure S1B-D), 
and for an EGFP-tagged Pcgf1 for which we had injected mRNA in early zygotes. Both 
proteins are part of the vPRC1 complex, also containing Kdm2b and Bcor, which 
localizes to unmethylated CpG islands in ESCs (Blackledge et al., 2014; Gao et al., 
2012; García et al., 1999) (Figure 1A). In contrast to cPRC1 subunits, we did not 
observe selective enrichment for either vPRC1 protein at pat-PCH though euchromatin 
of both pronuclei was labeled (Figure 1B). Nonetheless and despite the presence of 
DNA methylation (Figure S1E) we observed strong H2AK119ub1 labeling at pat-PCH 
arguing that these cPRC1 members, constituting matPRC1, are able to robustly modify 
chromatin at major satellites, classical sites of constitutive heterochromatin formation, 
irrespective of the local DNA methylation status.  
 
Cbx2 mediates PRC1 targeting to constitutive heterochromatin in Suv39h dn 
ESCs 
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 We previously showed that PRC1 localization at PCH is recapitulated in Suv39h 
dn ESCs when matPRC1 proteins Cbx2, Bmi1, and Phc2 are co-expressed with 
endogenous Rnf2 (Puschendorf et al., 2008). To investigate which of these matPRC1 
members may target the complex to PCH, we expressed the proteins individually in 
wild-type (wt) and Suv39h dn ESCs and quantified their enrichment at chromocenters 
relative to euchromatin using IF imaging approaches (Figure 1C, S1F). In mouse nuclei, 
chromocenters represent clusters of PCH regions from different chromosomes 
(Guenatri et al., 2004). Despite comparable expression levels (Figure S1G), only Cbx2 
was strongly enriched at chromocenters in Suv39h dn ESCs (Figure 1C). Next we 
examined whether Cbx2 targets functional PRC1 complexes to PCH in Suv39h dn 
ESCs. Indeed, we observed consistent labeling of chromocenters by endogenous Phc1 
and Rnf2 proteins and H2AK119ub1 upon expression of Cbx2-EGFP (Figure 1D). Since 
wt and Suv39h dn ESCs show similar levels of PRC1 and PRC2 proteins, H2AK119ub1 
and alkaline phosphatase activity (Figure S1H-I), these results are not a consequence 
of differences in availability of endogenous PRC1 proteins or differentiation status of the 
two cell lines.  
In embryos, EGFP-tagged Cbx2 localized to pat-PCH in Rnf2m-z+ zygotes though 
we did not observe recruitment of endogenous Bmi1 nor H2AK119ub1 enrichment at 
pat-PCH. These data argue that Cbx2-mediated assembly of PRC1 complexes at 
heterochromatin requires the Rnf2 subunit (Figure 1E) which is consistent with known 
protein-protein interactions between PRC1 components (Gao et al., 2012; García et al., 
1999). Altogether, these data indicate that Cbx2 targets active cPRC1 complexes to 
major satellites in pre-implantation mouse embryos and ESCs that are characterized by 
absence of H3K9me3 and HP1 proteins.   
 
Cbx2 targeting to PCH in Suv39h dn ESCs depends on both its chromo- and AT-
hook domains 
We next investigated which domain(s) in Cbx2 confer binding to PCH. Cbx2 
harbors a chromo domain (CDCbx2) that preferentially binds to H3K27me3 (Bernstein et 
al., 2006; Kaustov et al., 2011). This mark is strongly and moderately enriched at pat-
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PCH in zygotes and chromocenters in Suv39h dn ESCs, respectively (Peters et al., 
2003; Santos et al., 2005). Cbx2 also contains a conserved AT-hook (AT) close to 
CDCbx2 and two AT-hook like (ATL) motifs (Figure 2A-B). AT-hooks  bind to the minor 
groove of AT-rich DNA sequences, while ATL sequences are unlikely to bind DNA 
(Reeves and Nissen, 1990). Crucially, mouse major satellites underlying PCH are AT-
rich sequences. To identify the role of CDCbx2 and the AT-hook in PCH targeting, we 
impaired their binding abilities by introducing point mutations and scored the enrichment 
of tagged proteins on PCH relative to euchromatin in Suv39h dn ESCs (Figure S2). 
Whereas Cbx2-EGFP was strongly enriched at PCH, heterochromatic enrichment was 
significantly reduced for the Cbx2-CDF12A- and Cbx2-ATG78R-EGFP proteins (Figure 2C-
D), demonstrating that both domains contribute to PCH targeting. In contrast, point 
mutations in either or both ATL motifs did not impair PCH targeting (Figure S2C, S2D). 
PCH enrichment was completely lost upon double mutation of the CD and AT-hook, 
arguing that CDCbx2 and ATCbx2 together confer binding to PCH (Figure 2C-D). 
To further investigate the role of CDCbx2 and ATCbx2 in the association of Cbx2 to 
chromatin we performed Fluorescence Recovery after Photobleaching (FRAP) 
experiments. We observed a four-fold lower half fluorescence recovery time for both 
Cbx2-CDF12A and Cbx2-ATG78R mutations, compared to wt Cbx2, indicating a less stable 
association with PCH and faster turnover upon mutation of CD or AT (Figure 2E).  
Finally, we performed chromatin immunoprecipitation followed by quantitative 
PCR (ChIP-qPCR) to quantify the impact of CD and AT point mutations on Cbx2 
occupancy at major satellites. We observed robust Cbx2-EGFP enrichment at major 
satellites using well-controlled ChIP-qPCR conditions (Figure S2E). Mutation of either 
the CD or the AT-hook reduced occupancy at PCH, with an almost complete loss upon 
double mutation (Figure 2F). These data indicate that the CDCbx2 and ATCbx2 contribute 
to a similar extent to the recruitment of Cbx2 to PCH in Suv39h dn ESCs.  
 
Cbx2 targeting to hetero- and euchromatin in zygotes 
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 In vivo, pat-PCH acquires H3K27me3 concurrent with replication (Albert and 
Peters, 2009). Nonetheless, matPRC1 localizes already to pat-PCH in decondensing 
sperm nuclei shortly after fertilization (Puschendorf et al., 2008) suggesting that ATCbx2 
drives matPRC1 targeting at this stage of development. To test this hypothesis, we 
treated ESCs and embryos with the small compound distamycin A which interferes with 
the binding of AT-hook containing proteins to AT-rich satellite sequences in mouse and 
Drosophila by intercalating into the minor groove of DNA (Radic et al., 1992). IF and 
ChIP-qPCR experiments confirmed that distamycin A reduces Cbx2-EGFP localization 
at chromocenters and major satellites in Suv39h dn ESCs while heterochromatic 
localization of H3K9me3 and Hp1 was unaffected in wt cells (Figure S3A-E). In early 
mouse zygotes, PCH localization of endogenous matPRC1 components Cbx2 and Rnf2 
in decondensing sperm heads was effectively abrogated by distamycin A in a 
concentration dependent-manner (Figure 3A). Thus, these data demonstrate the 
importance of ATCbx2 at the onset of development in heterochromatic targeting of 
matPRC1 in an H3K27me3 independent manner.  
 To assess the importance of CDCbx2 and ATCbx2 for matPRC1 targeting in later 
stage embryos, we microinjected mRNA of various Cbx2-EGFP reporter constructs into 
early mouse zygotes shortly after fertilization and cultured them until pro-nuclear stage 
5 (PN5), just prior to the first cleavage division (Figure S3F). Full length Cbx2-EGFP 
was strongly enriched at pat-PCH, like the endogenous protein (Figure 3B) 
(Puschendorf et al., 2008). Unlike in Suv39h dn ESCs, however, the Cbx2-CDF12A 
mutation did not affect localization to pat-PCH, suggesting a greater contribution of the 
AT-hook to PCH binding in zygotes. This finding is consistent with our previous results 
showing Ezh2-independent targeting of matPRC1 to pat-PCH (Puschendorf et al., 
2008). Indeed, Cbx2-EGFP remains strongly enriched at pat-PCH in Ezh2m-z+ zygotes in 
which absence of the maternal enzyme prevents H3K27me3 establishment on the 
paternal pronucleus (Figure 3C).  
Similarly, the Cbx2-ATG78R mutation did not significantly reduce pat-PCH 
enrichment in wt zygotes (Figure 3B) suggesting a strong compensatory mechanism 
provided by CDCbx2. To test this possibility, we analyzed the Cbx2-CDF12A-ATG78R double 
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mutant in wt zygotes and observed a complete loss of signal at pat-PCH (Figure 3B). 
We also did not detect a signal in euchromatin of both pronuclei. To exclude the 
possibility that the double mutant protein is instable in embryos (Figure S2B), we tested 
the ATG78R construct in Ezh2m-z+ zygotes which lack H3K27me3 in the paternal genome. 
Consistently, we lost Cbx2-ATG78R localization at pat-PCH and euchromatin in Ezh2m-z+ 
compared to control conditions (Figure 3C). Thus, in contrast to Suv39h dn ESCs, 
CDCbx2 and ATCbx2 are each sufficient for efficient Cbx2 targeting to pat-PCH in one-cell 
embryos. The latter could in part be due to higher H3K27me3 levels at pat-PCH in 
embryos versus Suv39h dn ESCs and/or to differences in chromatin accessibility 
affecting the ability of the AT-hook to bind DNA.  
 
CDCbx2 and ATCbx2 mediate chromatin association  
To explore the role of CDCbx2 and ATCbx2 in euchromatin binding, we performed 
co-immunoprecipitation of wt and mutant Cbx2-EGFP transfected into HEK293 cells 
and probed for their association with H3K27me3-modified nucleosomes (Figure 4A). 
Although all Cbx2-EGFP proteins associated with Rnf2, mutation of CDCbx2 or ATCbx2 
resulted respectively in a strong and moderate reduction of immunoprecipitated 
H3K27me3-modified nucleosomes compared to wt Cbx2-EGFP protein. To test if such 
mutations could impair chromatin binding of Cbx2, we performed biochemical 
fractionation of protein lysates from ESCs transiently transfected with wt and mutant 
Cbx2-EGFP proteins (Figure 4B). Consistently, Cbx2-CDF12A and Cbx2-ATG78R mutants 
are less enriched in the chromatin fraction, and instead accumulate in nuclear soluble 
and cytoplasmic fractions. This effect was more pronounced for the double mutant 
protein arguing that Cbx2 association with chromatin requires both its CD and AT 
modules. 
We further used NMR spectroscopy to detail the mechanism by which Cbx2 
recognizes H3K27me3-marked chromatin. We investigated the binding of a short 
Cbx2CD-AT to a reconstituted recombinant nucleosome core particle modified with a 
methyllysine analog at H3K27 (H3Kc27me3-NCP) or a short H3K27me3 peptide (Figure 
4C). Cbx2CD-AT was either uniformly labeled with 15N (upper two panels) or specifically 
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labeled with 13C at Ile, Leu and Val residues (lower two panels) and changes in NMR 
resonance frequencies (chemical shift perturbations) were measured to identify 
residues in Cbx2CD-AT that change upon nucleosome or peptide binding. As expected, 
binding of a H3K27me3 peptide induced chemical shift perturbations only within the CD. 
Furthermore, the residues affected by peptide binding map to the known H3K27me3 
binding site of Cbx2CD as determined by X-ray crystallography (Kaustov et al., 2011). 
This indicates that in solution, the chromodomain of Cbx2CD-AT binds to the H3K27me3 
peptide in the same manner as the isolated CD, and there are no interactions of the AT 
hook domain or the linker region with the peptide. We next examined the chemical shift 
changes in Cbx2CD-AT upon binding to the H3Kc27me3-NCP which contains two AT-rich 
sequences (Figure 4C, first and third panels). Again we observed expected chemical 
shift perturbations in the CD, although the magnitudes of the changes were weaker 
compared to the H3K27me3 peptide. We attribute this difference to the known lower 
affinity of the alkylated cysteine methyllysine analogues compared to bona fide 
trimethyllysine (Seeliger et al., 2012). Importantly, in the presence of the H3Kc27me3-
NCP we observed significant changes in NMR chemical shifts in the linker between 
CDCbx2 and ATCbx2, the AT hook itself, and in the residues immediately after ATCbx2. 
These data show that regions of Cbx2CD-AT C-terminal to the CD are significantly 
involved in nucleosome binding (but not H3K27me3 binding). Furthermore, chemical 
shift values of the linker region when bound to H3Kc27me3-NCP are consistent with 
increased helical content suggesting a conformational change upon binding. Together, 
our NMR data are consistent with a coordinated twofold interaction of Cbx2CD-AT with 
H3K27me3-marked nucleosomes in which CDCbx2 binds the methyl mark and ATCbx2 
binds AT-rich regions of nucleosomal DNA.  
 
CDCbx2 directs ATCbx2 binding to DNA by integrating histone modification states 
 We have shown that matPRC1 is excluded from mat-PCH by the Suv39h 
pathway (Puschendorf et al., 2008). Surprisingly, micro-injection of the Cbx2-CDF12A 
construct in zygotes resulted in modest but significant accumulation of the protein as 
well increased H2AK119ub1 enrichment at mat-PCH compared to the Cbx2 control 
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construct (Figure 3B, 5A) demonstrating that functional matPRC1 complexes are 
targeted to these sites, regardless of the presence of H3K9me3, H4K20me3 and Hp1. 
Likewise, we observed only an increased localization of Cbx2-CDF12A but not of wt Cbx2 
at mat-PCH in Ezh2m-z+ zygotes (Figure S4A) ruling out the possibility that mat-PCH 
localization is driven by an increased availability of Cbx2 released from euchromatic 
sites. Indeed, matPRC1 components are sufficiently expressed to even bind to and 
modify PCH of two paternal genomes in triploid zygotes while mat-PCH is refrained 
from PRC1 activity (Figure 5B). Together, these data imply that a functional CDCbx2 
prevents ATCbx2 from binding to mat-PCH.   
 We next investigated whether the gain of PCH localization of Cbx2-CDF12A is due 
to the inability of the CD to read methylated histones, thereby enabling ATCbx2 to bind to 
DNA. We transiently transfected wt ESCs with a short CDCbx2-ATCbx2-EGFP reporter 
construct lacking the Pc-box domain to eliminate interactions with other PRC1 
components. As in zygotes, the CDF12A mutation as well as another aromatic cage 
mutation, CDW33A, enabled enrichment at PCH of wt ESCs without altering overall 
protein levels (Figures 5C, S4B) (Bernstein et al., 2006). Mutating additionally ATCbx2 
resulted in loss of PCH enrichment, confirming that the localization of CD mutants in wt 
cells is mediated by ATCbx2.  
 These results suggest that CDCbx2 and ATCbx2 function as one molecular unit 
such that the binding of ATCbx2 to specific loci is determined by CDCbx2 integrating the 
local chromatin status. This model predicts that the linker between CDCbx2 and ATCbx2 
controls the chromatin sensing capacity of the CD-AT unit. Indeed, our NMR data 
(Figure 4C) supports the idea that the linker is involved in nucleosome binding. To test 
whether the chromatin specific targeting effect of CDCbx2 is alleviated by a spatial 
separation of CDCbx2 and ATCbx2, we replaced the 14 amino acid linker sequence by a 
long flexible linker consisting of 10 ‘TGS’ repeats. We observed a similar gain in 
heterochromatin localization for the CDCbx2-flex-ATCbx2-EGFP as for the CDCbx2-F12A-
ATCbx2-EGFP reporter in wt cells (Figure 5C) suggesting that the longer linker uncouples 
the coordinated recognition of chromatin by Cbx2CD-AT. Indeed, introduction of the 
CDF12A mutation in such construct (CDCbx2-F12A-flex-ATCbx2-EGFP) did not additionally 
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improve heterochromatic enrichment (Figure 5C). Intriguingly, linking CDCbx2 to even 
more potent DNA-binding AT-hooks of the high mobility group protein HMGA1 (AT2 and 
AT3) reduced heterochromatic localization of such fusion protein in wt ESCs, as 
measured by IF and ChIP-qPCR. Inclusion of the CDF12A mutation or a long flexible 
linker improved the localization of the EGFP reporters to chromocenters (Figure 5D-E, 
S4C). These results show that CDCbx2 effectively reduces DNA binding of nearby high 
affinity AT-hooks in the context of a Suv39h-dependent H3K9me3-modified chromatin 
configuration. Moreover, the short linker sequence between CDCbx2 and ATCbx2 is 
required to sense the specific heterochromatic status for localization of PRC1.  
  
Alanine 14 defines chromatin targeting specificity of Cbx2 
Given that H3K9me3-labeled chromatin occludes Cbx2 from binding we 
wondered whether increasing the affinity of CDCbx2 for H3K9me3 would enable Cbx2 
localization at PCH in wt ESCs. Despite high conservation, CDs of Drosophila and 
mammalian Cbx and Suv39h proteins harbor several variable amino acids (Figure 6A, 
6B). Comparative analysis of crystal and NMR structures of Cbx CDs revealed that 
most variant amino acids are not in proximity of the H3 N-terminus and may therefore 
not be critical for recognition of methylated H3 (Kaustov et al., 2011). An exception is 
residue 14 (with respect to Cbx2) which resides within a hydrophobic cavity that 
embraces the H3 N-tail close to the methylated lysine. This residue is an alanine in the 
CDs of Cbx2 and dPC which preferentially bind to H3K27me3, whereas it is a valine in 
CDs of Cbx4, Cbx7, HP1 proteins and the Suv39h HMTs, all recognizing H3K9me3 
(Figure 6A). Interestingly, the classical EMS-induced SU(VAR)2502 loss-of-function allele 
of dHP1 harbors a V-to-M substitution of this residue (Platero et al., 1995). Consistently, 
the corresponding mouse Hp1 V23M mutant has reduced affinity for H3K9me2 
peptides (Lachner et al., 2001) and a V23A mutant fails to localize to chromocenters in 
wt ESCs (Figure S5A-C). 
 In contrast, the “inverse” A14V substitution in CDCbx2 increased its affinity for 
H3K9me3 while leaving the affinity for H3K27me3 unaffected (Figure 6B). Consistent 
with representing a gain-of-function, the A14V substitution increased the PCH 
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localization of CDCbx2-ATCbx2- and even of CDdPC-ATCbx2-EGFP reporters in wt ESCs, 
indicating functional conservation of the residue in Cbx2 and dPC (Figure 6C). We also 
observed an increased localization of full-length Cbx2-CDA14V at mat-PCH compared to 
control showing that the A14V replacement modulates chromatin binding in vivo (Figure 
6D). Thus, these experiments demonstrate that the exclusion of Cbx2 from mat-PCH 
and PCH in wt ESCs can be overcome by increasing the binding affinity of CDCbx2 for 
H3K9me3.  
 
Hp1 prevents PRC1 binding to mat-PCH in zygotes 
 The previous experiments suggest that CDCbx2 effectively prevents ATCbx2 from 
binding major satellites by competing with HP1 proteins for association with chromatin. 
To test this idea, we aimed at removing HP1 proteins from PCH using a genetic 
approach. In mouse, three dHP1 orthologs are expressed in most cell types including 
ESCs in which chromocenters are predominantly marked by Hp1 (Cbx5), Hp1 
(Cbx1), and to a lesser extent Hp1 (Cbx3) (Minc et al., 1999). In mouse zygotes, only 
Hp1 is enriched at maternal PCH in a Suv39h2-dependent manner correlating with 
H3K9me3 (Figure S6A) (Puschendorf et al., 2008). Since Hp1 and Hp1 proteins are 
not present in nuclei of zygotes (Figure S6A) (Meglicki et al., 2012), we generated mice 
conditionally deficient for Hp1 during oogenesis and that would thus lack maternally 
provided protein during pre-implantation development. Indeed, Hp1 protein was not 
detectable in Hp1m-z+ zygotes (Figure 7A). Moreover, neither Hp1 nor Hp1 were 
significantly up-regulated (Figure S6A), ruling out any possible compensatory 
mechanisms. Strikingly, all canonical matPRC1 proteins and H2AK119ub1 accumulated 
on mat-PCH as on pat-PCH in Hp1m-z+ zygotes (Figure 7A, S6B), as observed for 
Suv39hm-z+ zygotes (Figure S6G) (Puschendorf et al., 2008). This result shows that loss 
of Hp1 creates a permissive state for matPRC1 binding at mat-PCH. Interestingly, we 
also observed an enrichment of H3K27me3 at mat-PCH in Hp1m-z+ zygotes, thereby 
presumably reinforcing Cbx2 binding to mat-PCH (Figure 7B). Together, these data 
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demonstrate that Hp1, by binding to Suv39h-mediated H3K9me3, creates a chromatin 
state that is non-permissive for Cbx2, matPRC1 and PRC2 binding to mat-PCH. 
 
DISCUSSION 
 
CDCbx2 and ATCbx2: two reader domains mediating cPRC1 targeting 
We elucidate here the molecular mechanisms underlying targeting of PRC1 to 
major satellites and the control thereof by Hp1 in mouse early embryos. These 
mechanisms are distinct from those proposed to drive alternative heterochromatin 
formation by vPRC1 at PCH in Suv39h dn or Dnmt TKO ESCs (Cooper et al., 2014; 
Saksouk et al., 2014). We show that targeting of catalytically active matPRC1 to pat-
PCH in zygotes is mediated by the CD and AT-hook of Cbx2. Mutational studies of 
CDCbx2 and ATCbx2 and competition experiments with distamycin A indicate that ATCbx2 
binds to AT-rich major satellites thereby targeting matPRC1 to heterochromatin in a 
PRC2-independent manner, as observed in vivo at pat-PCH following fertilization, 
before the acquisition of H3K27me3. Mutational studies, combined with Ezh2 deficiency 
conditions, show that the interaction between CDCbx2 and H3K27me3 contributes to 
Cbx2 association at PCH and euchromatin in vivo. The observed H3K27me3 selectivity 
is consistent with the in vitro binding specificity of CDCbx2 (Bernstein et al., 2006; 
Kaustov et al., 2011). Biophysical and biochemical experiments show that both modules 
increase the affinity of Cbx2 for chromatin, thereby potentially controlling PRC1 
targeting to specific epigenetically marked loci in the genome.  
Whereas CDCbx2 and ATCbx2 are each sufficient for Cbx2 targeting to pat-PCH in 
zygotes, they contribute in an additive manner to PCH binding in ESCs. Such cell type 
specific binding properties may reflect possible differences in DNA accessibilities and/or 
H3K27me3 occupancies, resulting from dynamic changes in chromatin during the 
establishment versus maintenance of the repressive state in early embryos versus 
ESCs, respectively.   
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 MatPRC1 members and H2AK119ub1 localize in zygotes at pat-PCH despite the 
presence of DNA methylation within this compartment. In contrast, we did not detect 
enrichment of endogenous Rybp, a common component among distinct vPRC1 
complexes (Blackledge et al., 2014; Gao et al., 2012), nor of exogenous Pcgf1-EGFP, 
although transcripts of these and other vPRC1 members including Kdm2b are 
maternally provided to the zygote. These data support the notion that chromatin 
targeting of vPRC1 but not matPRC1 is inhibited by DNA methylation (Cooper et al., 
2014; Saksouk et al., 2014).   
 Proteins or complexes bind to chromatin often via multiple reader domains that 
each interact with relatively low affinity to modifications on histones or DNA 
(Eustermann et al., 2011; Ruthenburg et al., 2011; Cheng and Blumenthal, 2010). 
Among Cbx proteins of the PcG family, this feature is unique to Cbx2. Others contain 
only a CD, which for Cbx4 and Cbx7 display moderate affinity to H3K9me3 and 
H3K27me3 (Figure 6B) whereas no interactions could be measured for Cbx6 or Cbx8  
in vitro (Bernstein et al., 2006; Kaustov et al., 2011). Consistently, other PcG-Cbx 
proteins besides Cbx2 do not significantly bind to PCH in wt nor Suv39h dn ESCs 
(Figure S5F; data not shown). Linking ATCbx2 to either CDCbx4 or CDCbx7, however, 
resulted in targeting of chimeric reporters to PCH (Figure S5E) suggesting that the 
combination of CDCbx4 or CDCbx7 with ATCbx2 provides the chimeric proteins sufficient 
affinity to compete with HP1 proteins for binding to PCH. Accordingly, loss of H3K9me3 
affinity via a V13A mutation impaired PCH localization (Figure 6B, S5E). In zygotes, 
however, we observed some PCH enrichment for full length Cbx7-EGFP but not for 
Cbx4-EGFP whereas Cbx2-EGFP was more strongly enriched (Figure S5G). These 
data are consistent with previously discussed cell type specificities, differences in 
H3K27me3 affinities of respective CDs, the role of ATCbx2 and possibly of its neighboring 
amino acids in binding to H3K27me3-modified nucleosomes (Figure 4C, 6B).  
 
CDCbx2 and ATCbx2 functions as one molecular unit 
Besides enhancing chromatin affinity, CDCbx2 and ATCbx2 specify together also 
binding selectivity. Mutating the CD or uncoupling CDCbx2 and ATCbx2 by increasing the 
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distance between these modules enabled targeting to heterochromatic sites bound by 
proteins of the Suv39h/HP1 pathway. We therefore propose that CDCbx2 and ATCbx2, 
interconnected by a short linker, function as one molecular unit integrating the histone 
methylation and HP1 state for Cbx2 binding to chromatin. Correspondingly, Hp1 
deficiency in zygotes allows matPRC1 localization at mat-PCH. In such embryos, 
H4K20me3 levels are reduced at mat-PCH, while H3K9me3 is largely unchanged 
(Figure S6C, D), which is consistent with Suv4-20h HMTs acting downstream of HP1 
proteins (Schotta et al., 2004). Cbx2-EGFP did not localize to PCH in Suv4-20h dn 
ESCs, marked by Hp1 but lacking H4K20me3 (Figure S6E, F), indicating that Hp1 
rather than H3K9me3 or any Suv4-20h-dependent process is inhibitory to Cbx2 binding. 
Whether such mechanism of steric hindrance is modulated by post-translational 
modifications on Cbx2 or HP1 proteins (Hatano et al., 2010), and whether it would 
contribute to parental specific gene repression programs during early embryogenesis 
remain intriguing questions.  
 
Hp1 inhibits H3K27me3 accumulation at mat-PCH 
Surprisingly, we also detected H3K27me3 enrichment at mat-PCH in Hp1m-z+ 
embryos despite unaltered H3K9me3 levels. These results are in accordance with 
reports showing co-existence of H3K9me3 and H3K27me3 at loci (Bilodeau et al., 2009) 
and that H3K9me3 does not inhibit PRC2 activity (Schmitges et al., 2011). They further 
argue that PRC2 recruitment and/or activity is negatively regulated by HP1 which may 
explain the exclusive localization of H3K27me3 at PCH lacking H3K9me3 in Dnmt TKO 
ESCs (Cooper et al., 2014). Although artificial tethering of a minimal Rnf2/Pcgf4 
complex and resulting H2AK119ub1 are sufficient for H3K27me3 deposition at PCH, 
even in wt ESCs (Cooper et al., 2014), H3K27me3 localization at pat-PCH is 
independent of Rnf2 function in wt zygotes and likely at mat-PCH in Hp1m-z+ embryos 
as well (Puschendorf et al., 2008). Hence, the function of Bend3 in H3K27me3 
deposition in vivo awaits further investigation (Saksouk et al., 2014). If relevant, it will be 
important to determine to what extent Bend3 recruitment to PCH and euchromatin is 
controlled by Hp1 and DNA methylation reprogramming events in early embryos.  
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EXPERIMENTAL PROCEDURES 
Constructs 
 Constructs for N-terminal enhanced GFP (EGFP) fusion proteins of Rnf2 and 
Phc2 (BD Biosciences) and 3xFlag-Bmi1 were kindly provided by Dr. Koseki. 
Constructs for C-terminal EGFP fusions of Cbx2, Cbx4, Cbx6, Cbx7 and Cbx8 were 
generously provided by Dr. Bernstein (Bernstein et al., 2006). Point mutations were 
generated by site-directed mutagenesis (Stratagene). Hmga1 and Pcgf1 were cloned by 
PCR from NIH3T3 and CCE cDNA respectively. For microinjection, constructs were 
cloned into a pcDNA3.1-poly(A) vector kindly provided by Dr. Yamagata (Yamagata et 
al., 2005). 
 
Mice and Cell Lines 
 Ezh2m-z+ zygotes have been reported previously (Puschendorf et al., 2008). ESC 
clone EPD0027_2_ H02 (EUCOMM) was used to generate Cbx1 (Hp1) conditionally 
deficient mice. Wt, Suv39h dn (Lehnertz et al., 2003) and Suv4-20h dn (Schotta et al., 
2004) ESCs were transfected with fusion constructs using Lipofectamine 2000 
(Invitrogen). Flow cytometry, FRAP, in vitro fertilization, micro-injection of CD1 or 
C57Bl6/J zygotes and culture of embryos is described in the Supplemental 
Experimental Procedures. 
 
IF staining, Western Blot, IP and ChIP 
IF staining and Western blot analysis were done as described previously (Posfai 
et al., 2012; Puschendorf et al., 2008; Tardat et al., 2010). Protocols and reagents for 
IF, image quantification, statistical analysis, protein extraction, IP, ChIP and antibodies 
is given in the Supplemental Experimental Procedures and Table S1.  
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Fluorescence Polarization and NMR 
Biophysical analyses were performed as described before (Kaustov et al., 2011). 
Detailed information is available in the Supplemental Experimental Procedures. 
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Figure 1: Cbx2-PRC1 complexes are targeted to constitutive heterochromatin in 
embryos and Suv39h dn ESCs 
(A) Schematic representation of cPRC1 and vPRC1. Arrows refer to catalytic activities 
while dashed lines indicate binding interactions.  
(B) IF of cPRC1 and vPRC1 components in wt PN5 zygotes. The cPRC1 component 
Phc2, the common catalytic subunit Rnf2 and H2AK119ub1 are enriched at pat-PCH 
(arrows). vPRC1 components Rybp and tagged Pcgf1-EGFP show no enrichment at 
pat-PCH. 
(C) Localization of exogenously expressed matPRC1 components in nuclei of wt and 
Suv39h dn mESCs. Whereas 3xFlag-Bmi1 was detected by IF, EGFP fluorescence was 
directly measured. Chromocenters are brightly stained with DAPI. Quantification of 
protein enrichment at PCH is presented as a ratio of fluorescence intensity at PCH over 
euchromatin (see Figure S1F for details).  
(D) IF for H2AK119ub1 and endogenous Phc1 and Rnf2 in Suv39h dn ESCs transiently 
expressing Cbx2-EGFP or EGFP alone.  
(E) Localization of Cbx2-EGFP, Bmi1 and H2AK119ub1 at pat-PCH of PN5 stage 
zygotes (arrows) either wt or Rnf2 deficient (Rnf2m-z+). Box plots show quantification of 
fluorescence intensity at PCH (in arbitrary units (A.U.)).  
The number of cells and embryos analyzed are shown between brackets. *p<0.05; 
**p≤0.01; ***p≤0.001. 
 
Figure 2: CDCbx2 and ATCbx2 regulate Cbx2 targeting to PCH in Suv39h dn ESCs 
(A) Sequence alignment of N-terminal amino acids of five mouse dPC orthologs 
containing chromodomains, and an AT-hook in Cbx2. Blue arrows: aromatic cage 
residues that enable methyl-lysine binding by CDs. Green arrows: PRGRP consensus 
sequence. 
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(B) Schematic representation of 5 mammalian PcG Cbx proteins. Chromodomains in 
purple, AT-hook motif in green, AT-hook like (ATL) motifs in yellow, PcBox in blue. 
(C) Nuclear localization of full length Cbx2–EGFP constructs with mutations in Suv39h 
dn ESCs. 
(D) Relative enrichment of Cbx2-EGFP constructs at PCH over euchromatin in Suv39h 
dn ESC nuclei. 
(E) FRAP of Cbx2-, Cbx2-CDF12A-, Cbx2-ATG78R-EGFP was performed on 
chromocenters in Suv39h dn ESCs after transient transfection with indicated constructs 
(the bleached region is indicated by a white arrow, top panel). Recovery kinetics were 
measured over a period of 60 sec (lower panel). The estimated recovery half-times are 
8.72 ± 5.06s, 2.26 ± 1.12s and 2.13 ± 1.01s for Cbx2-, Cbx2-CDF12A- and Cbx2-G78R-
EGFP respectively (values represent mean ± SD; n = ~25 per construct). 
(F) Enrichment of Cbx2-EGFP constructs at PCH in Suv39h dn ESCs as measured by 
ChIP-qPCR analysis of mouse major satellite repeats. Data are represented as percent 
of input chromatin. Error bars represent SD. 
 
Figure 3: Cbx2 targeting to hetero- and euchromatin in zygotes. 
(A) IF images (left panel) and quantification of Cbx2 and Rnf2 fluorescence signal at 
PCH of decondensing sperm heads in PN0 stage zygotes, untreated (control) or treated 
with 20µM and 50µM distamycin A.  
(B) Localization of Cbx2-EGFP constructs at PCH of maternal and paternal pronuclei of 
PN5 stage one-cell embryos (arrows, left panel). Box plots show quantification of EGFP 
fluorescence intensity at mat-PCH, pat-PCH and euchromatin for each construct  
(C) Localization of Cbx2 and Cbx2-ATG78R EGFP constructs in paternal PCH and 
euchromatin of wt and Ezh2m-z+ zygotes (left panel). Box plots show quantification of 
EGFP and H3K27me3 fluorescence intensity at mat-PCH and euchromatin for each 
construct.  
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The number of embryos analyzed is shown between brackets. *p<0.05; ***p≤0.001; ns: 
not significant. 
 
Figure 4: CDCbx2 and ATCbx2 control chromatin binding. 
(A) Co-IP of Cbx2 with H3K27me3-modified nucleosomes. Whole-cell extracts from 
HEK293 cells expressing Cbx2-EGFP constructs were IP-ed with anti-EGFP antibody 
and analyzed by immunoblot with indicated antibodies. 
(B) Sub-cellular distribution of Cbx2-EGFP proteins in ESCs. -Tubulin and Lamin A/C 
were used as controls for cytoplasmic and chromatin fractions. 
(C) Structural basis for Cbx2 interaction with the nucleosome. Cbx2CD-AT complexes with 
methyllysine analog H3Kc27me3-NCP and H3K27me3 peptide (residues 19-33) were 
prepared by titrating aliquots of nucleosome or peptide into the indicated isotope-
labeled protein. Top panels: 1H-15N chemical shift perturbations (CSP) for Cbx2CD-AT 
(residues 9-88) vs residue number when bound to either a recombinant modified 
nucleosome core particle H3Kc27me3-NCP (1:2 (blue) and 1:3 (maroon) molar ratios, 
Cbx2:nucleosome)  or a synthetic H3K27me3 peptide (1:1 (light blue), 1:3 (pink) and 1:6 
(maroon) molar ratios, Cbx2:peptide, second panel). Open circles indicate either 
unassigned peaks or peaks that can not be observed in the [1H,15N]-TROSY spectrum 
before titration. Solid black circles correspond to Prolines which do not have peaks. Red 
circles indicate peaks that disappear upon binding. Bottom panels: CSP weighted 
average of the [1H,13C] methyl chemical shift changes of Cbx2CD-AT with Ile, Leu and Val 
residues selectively 13C-labeled and titrated with the H3Kc27me3 nucleosome (1:1 
(blue), 1:2 (light blue) and 1:3 (dark blue) molar ratios, Cbx2:nucleosome) or to the 
synthetic H3K27me3 peptide (1:3 (blue) and 1:6 (maroon) molar ratios, Cbx2:peptide). 
CSP were calculated using the equation Δ(δ1H-15N) = [(Δδ1H)2 + (Δδ15N/5)2]1/2 and 
Δ(δ1H-13C) = [(Δδ1H)2 + (Δδ13C/4)2]1/2, respectively. 
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Figure 5: CDCbx2 regulates DNA binding of ATCbx2 by integrating histone 
modification states. 
(A) Localization of Cbx2- and Cbx2-CDF12A-EGFP constructs and H2AK119ub1 staining 
at PCH of maternal pronuclei of PN5 stage zygotes (arrows). Box plots showing 
quantification of EGFP and H2AK119ub1 fluorescence intensity at mat-PCH for each 
indicated construct.  
(B) IF of Rnf2 and H2AK119ub1 at pat-PCH of two paternal genomes in triploid mouse 
zygotes.  
(C) Schematic representation of Cbx2-EGFP short reporter constructs and 
quantification of their PCH enrichment in wt ESCs.  
(D) Schematic representation of CDCbx2 and ATHmga1 fusion proteins. Box plots represent 
quantification of EGFP signal on PCH relative to euchromatin for the indicated EGFP 
tagged constructs.  
(E) Histogram for EGFP ChIP-qPCR analysis of mouse major satellites in wt ESCs 
upon transient transfection with indicated CDCbx2-ATHmga1 fusion proteins. Data are 
represented as percent of input chromatin. Error bars represent SD. 
Asterisks refer to inserted point mutations. The number of embryos or cells analyzed 
are shown between brackets. *p<0.05; ***p≤0.001. 
 
Figure 6: Alanine 14 defines chromatin targeting specificity of Cbx2. 
(A) Sequence alignment of the CDs of dPC, dHP1 and their murine orthologs, and of 
the mouse Suv39h HMTs. 
(B) Dissociation constant (Kd) values for mutant and control CDs of Cbx proteins with 
methylated peptides. Kds were designated as >500µM when interactions were too weak 
to determine the Kd. Control values are from Kaustov et al. (2011). 
(C) EGFP images and quantification of PCH enrichment of chimeric EGFP reporters 
containing the CD of Cbx2 or dPC fused to ATCbx2 with or without the A14V mutation.  
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(D) EGFP images and quantification of EGFP fluorescence intensity at mat-PCH and 
pat-PCH for the indicated constructs in wt zygotes.  
The numbers of embryos analyzed are shown between brackets. ***p≤0.001; ns: not 
significant. 
 
Figure 7: Hp1 prevents PRC1 binding to mat-PCH in zygotes. 
(A) IF showing enrichment of matPRC1 components Cbx2, Rnf2, and H2AK119ub1 at 
mat-PCH in Hp1m-z+ zygotes but not in wt PN5 zygotes (arrows). Box plots show 
quantification of fluorescence intensity for indicated antibodies at mat-PCH and pat-
PCH in wt and Hp1m-z+ zygotes.  
(B) IF analysis showing increased levels of H3K27me3 at mat-PCH (arrows). Box plot 
shows quantification of fluorescence intensity of H3K27me3 at mat-PCH in wt and 
Hp1m-z+ zygotes.  
(C) matPRC1 is targeted to pat-PCH in zygotes by CDCbx2 binding to Ezh2-mediated 
H3K27me3 and ATCbx2 binding to DNA (presumably to major satellites). At mat-PCH, 
Cbx2 binding is prevented by maternally provided Hp1β bound to H3K9me3 via its CD. 
PRC2 targeting and/or activity is also inhibited by Hp1β. 
The number of embryos analyzed is shown between brackets. **p≤0.01; ***p≤0.001; ns: 
not significant. 
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Figure S1 (related to Figure 1).
(A) Plots showing expression data of cPRC1, vPRC1, Rnf2 and Ring1 subunits during mouse early embryonic development. Expression of Zp3, 
Pouf51 and Hnrnpr are shown as reference. Data were extracted from RNA-sequencing performed in oocytes (Oo), 1-Cell (C1), 2-Cell (C2), and 
4-Cell (C4) stage and represented as Log2 of RPKM (Park et al., 2013). 
(B) Western blot analysis showing the specificity of the Rybp antibody used in Figure 1B. Mouse ESCs were treated with siRNA against Rybp 
(siRybp-1, siRybp-2, siRybp-3, or a mixture of the 3 siRNA: siRybp-1-2-3) or transfected with an EGFP tagged Rybp. Endogenous (endo) Rybp 
protein levels decrease in cells transfected with Rybp siRNAs, compared to control siRNA (siSCR). The Rybp antibody can detect exogenous (exo) 
Rybp-EGFP (asterisk indicates degradation product). The Rybp antibody was a kind gift from M. Vidal.
(C) Rybp IF of mouse ESCs expressing a control (siSCR) or Rybp (siRybp-1) siRNA.
(D) Rybp IF of mouse ESCs transiently expressing an EGFP tagged Rybp.
(E) IF for H2AK119ub1 and 5mC in wild-type zygotes (n=12). Paternal PCH is labelled for both H2AK119ub1 and 5mC (white arrow).
(F) Scheme of the method used for scoring and representing the data from the automatic quantification of the immunofluorescence (IF) signal in 
ESCs. IF images are scanned with an in-house developed software (programmed in Matlab) that first identifies EGFP or antibody staining positive 
cells. Then, in each positive cells, masks are created using the DAPI staining to identify PCH and euchromatic regions (Eu) within the nucleus. Using 
these previously defined regions, mean intensity of fluorescence are measured in PCH and Eu and a ratio is calculated for each individual cell. Data 
are then plotted with SigmaPlot and the results are tested for significance with the Mann-Whitney Rank Sum Test. As an example, scoring of the IF 
signal of Hp1β in wild-type and Suv39h dn ESCs is shown.
(G) FACS analysis of the EGFP signal in wild-type and Suv39h dn ESCs transiently transfected with the indicated proteins. Representative FACS 
plots used for quantification of the EGFP signal from mock and transfected cells are shown (upper panel). A histogram shows the percentage of 
EGFP positive cells for the indicated proteins (lower panel). Results from wild-type and Suv39h dn ESCs are shown in black and grey respectively.
(H) Alkaline Phosphatase (AP) staining of wild-type and Suv39h dn ESCs.
(I) Western blotting of proteins from the H3K9/HP1 and Polycomb (PRC1 and PRC2) pathways and related histone modifications in wild-type and 
Suv39h dn ESCs.
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Figure S2 (related to Figure 2).
(A) Histogram for FACS analysis of wild-type and Suv39h dn ESCs transiently expressing the indicated EGFP-tagged full length Cbx2 constructs.
(B) Western blotting of full-length Cbx2 and point mutant constructs in wild-type and Suv39h dn ESCs. Cbx2 constructs were transiently transfected 
in ESCs before detection with a GFP antibody. Lower Cbx2-EGFP protein levels in unsorted population of Suv39h dn ESCs reflects lower frequen-
cies of transfection (Figure S2A) rather than differential expression levels between individual wild-type versus Suv39h dn ESCs. β-Tubulin is used 
as a loading control.
(C) Mutations introduced into the chromodomain, AT-hook and ATL motifs of Cbx2.
(D) Classic quantification of enrichment of different Cbx2-EGFP constructs at PCH relative to euchromatin in Suv39h dn ESCs nuclei (shown as % 
of EGFP positive cells showing enrichment on PCH). Numbers in brackets refer to numbers of cells scored.
(E) Chromatin immunoprecipitation (ChIP) controls in wild-type and Suv39h dn ESCs. Hp1β binding to major satellites is impaired in Suv39h dn 
ESCs, as expected. Cbx2-EGFP binds the promoter of Cdx2 and Gata4 in both wild-type and Suv39h dn ESCs. Cbx2-EGFP binds strongly to major 
satellites in Suv39h dn ESCs compared to wild-type cells. Primers used to amplify mouse major satellite DNA (Martens et al., 2005; Peters et al., 
2003), or regions 300bp and 400bp upstream of the TSS of Cdx2 and Gata4 respectively (Alder et al., 2010) were previously described. Results from 
wild-type and Suv39h dn ESCs are shown in black and grey respectively.
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Figure S3 (related to Figure 3).
(A) Distamycin A treatment results in loss of Cbx2-EGFP enrichment at chromocenters in Suv39h dn ESCs. In wild-type cells, distamycin A treatment 
does not impair H3K9me3 and Hp1β localization. Representative picture of control and distamycin A-treated wild-type and Suv39h dn ESCs are 
shown.
(B) Quantification of enrichment of Cbx2-EGFP at PCH relative to euchromatin in wild-type and Suv39h dn ESCs treated with 50µM distamycin A for 
2hr. 
(C) Histogram for FACS analysis of the EGFP signal in wild-type and Suv39h dn ESCs transiently transfected with Cbx2-EGFP -/+ treatment with 
distamycin A. Results from wild-type and Suv39h dn ESCs are shown in black and grey respectively.
(D) Western blotting analysis shows that the presence of distamycin A does not alter Cbx2-EGFP nor Hp1β protein stability in both wild-type and 
Suv39h dn ESCs. βtubulin is used as a loading control.
(E) Histogram for EGFP ChIP-qPCR analysis of mouse major satellite repeats in wild-type and Suv39h dn ESCs upon transient transfection with 
Cbx2 (full length) –EGFP ± distamycin A treatment. Data are represented as percent of input chromatin. Error bars represent SD.
(F) Scheme of the method used for scoring and representing the data from immunostaining in zygotes. Using Image J (National Institute of Health), 
we identify and draw regions of interest: PCH, euchromatin and background from the DAPI channel. The mean intensity of fluorescence of PCH and 
euchromatin is then measured in each channel from non-saturated images and normalized to background. The resulting fluorescence intensities, 
indicated as arbitrary units (A.U.), are plotted using SigmaPlot and the results are tested for significance with the Mann-Whitney Rank Sum Test. As 
an example, scoring of the IF signal of Bmi1 at PCH in wild-type zygotes is shown. As expected Bmi1 is significantly more localized to pat-PCH, than 
mat-PCH.
***p≤0.001; ns: not significant. Numbers in brackets refer to number of cells or embryos scored.
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Figure S4 (related to Figure 5).
(A) Localization of Cbx2-EGFP and Cbx2-CDF12A-EGFP constructs in maternal and paternal pronuclei of wild-type and Ezh2 maternally deficient 
(Ezh2m-z+) zygotes (left panel). Box plots show quantification of EGFP fluorescence intensity at mat-PCH and pat-PCH for each construct (right 
panel).
(B) Western blotting of Cbx2-EGFP short reporter and point mutant constructs in ESCs. Cbx2 reporter constructs were transiently transfected in 
ESCs before detection with a GFP antibody. β-Tubulin is used as a loading control.
(C) Western blotting of CDCbx2 and ATHmga1 fusion proteins and point mutant constructs in ESCs. Cells were transiently transfected with the indicated 
constructs. Fusion proteins were detected with a GFP antibody. β-Tubulin is used as a loading control.
*p<0.05; **p≤0.01; ns: not significant. The number of embryos analyzed is shown between brackets.
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Figure S5 (related to Figure 6).
(A) IF localization of 3xMyc-Hp1β and 3xMyc-Hp1βV23A in mouse ESCs transiently transfected with the indicated constructs.
(B) Quantification of the enrichment of exogenous Hp1β proteins (Myc-tag IF) on PCH shown in (A). 
(C) Western blot analysis of mouse ESCs transiently transfected with the indicated Hp1β constructs. β-Tubulin is used as a loading control.
(D) Western blotting of the chimeric EGFP short reporter and point mutant constructs in ESCs. Cells were transiently transfected with the indicated 
constructs. Fusion proteins were detected with a GFP antibody. β-Tubulin is used as a loading control.
(E) Quantification of PCH enrichment of chimeric EGFP reporters containing the CD of Cbx4 or Cbx7 fused to ATCbx2. The Valine to Alanine mutation 
impairs PCH localization of Cbx4 and Cbx7 reporters in wild-type ESCs.
(F) EGFP localization of Cbx4-, Cbx6-, Cbx7- and Cbx8-EGFP fusion proteins in Suv39h dn ESCs (left panel).  Quantification of the enrichment of 
exogenous EGFP tagged Cbx proteins on PCH in Suv39h dn ESCs (right panel).
(G) Localization of Cbx2, Cbx4 and Cbx7 EGFP constructs in paternal PCH and euchromatin of wild-type zygotes.
Numbers in brackets refer to number of cells scored (***p≤0.001).
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Figure S6 (related to Figure 7).
(A) IF analyses showing that expression levels and localization of Hp1α and Hp1β proteins are not changed in Hp1βm-z+ compared to wild-type PN5 
zygotes.
(B) IF localization of Bmi1 at PCH in maternal and paternal pronuclei of Hp1βm-z+ zygotes compared to wild-type (arrows). Box plots show the quantifi-
cation of fluorescence intensity for Bmi1 at mat-PCH and pat-PCH in wild-type and Hp1βm-z+ zygotes. 
(C, D) IF analyses show absence of anti-Hp1β signal and reduced levels for maternally inherited H4K20me3 in Hp1βm-z+ versus wild-type zygotes. 
H3K9me3 levels are comparable between genotypes. Box plots show quantification of fluorescence intensity for indicated antibodies at mat-PCH in 
wild-type and Hp1βm-z+ zygotes. 
(E, F) IF localization of Cbx2-EGFP, H4K20me3 and Hp1β in wild-type and Suv4-20h dn ESCs. Percentages indicate cells that display the depicted 
phenotype.
(G)  IF analyses showing that matPRC1 components Cbx2, Rnf2, and Bmi1 are enriched at mat-PCH in Suv39h2m-z+ zygotes but not in wild-type PN5 
zygotes (arrows). Box plots show quantification of fluorescence intensity for the indicated antibodies at mat-PCH and pat-PCH in wild-type and 
Suv39h2m-z+ zygotes.
*p≤0.05; **p≤0.01; ***p≤0.001; ns: not significant. The number of embryos analyzed is shown between brackets.
Table S1: List of antibodies used in this study. 
 Antibody Origin Ref WB IF ChIP 
PRC1 Bmi1 Upstate 05-637  1:200  
 Rnf2/Ring1b Active Motif 39663 1:1000 1:300  
 Cbx2 A.Otte   1:300  
 Phc1 SIGMA HPA006973 1:1000   
 Phc1 Active Motif 39724  1:300  
 Phc2 H.Koseki   1:200  
 Cbx7 Abcam ab21873 1:1000 1:300  
 Rybp Abcam ab5976 1:2000   
 Rybp M.Vidal  1:2000 1:500  
 H2AK119ub1 Cell Signaling 8240 1:2000 1:500  
PRC2 Ezh2 Cell Signaling 5246 1:1000   
 Suz12 Cell Signaling 3737 1:1000   
 EED A.Otte  1:1000   
 H3K27me3 Upstate 07-449 1:1000 1:500  
 H3K27me3 Active Motif 39156 1:1000 1:500  
H3K9/HP1 Suv39h1 Cell Signaling 8729 1:1000   
 ESET Upstate 07-378 1:1000   
 G9a Cell Signaling 3306 1:1000   
 Hp1α Euromedex 2HP-2G9-AS 1:1000 1:300  
 Hp1β Serotec MCA 1946 1:1000 1:500 4µg 
 Hp1γ Euromedex 
2MOD-1G6-
AS 1:1000 1:300  
 H3K9me3 Upstate 07-442 1:1000   
 H3K9me3 IMP   1:500  
 H4K20me3 IMP   1:500  
 5mC Eurogentec 
BI-MECY-
0100  1:400  
Controls GFP Roche 11814460001 1:1000 1:200 4µg 
 H3K4me3 Upstate 07-473 1:1000   
 βtubulin SIGMA T 4026 1:5000   
 Lamin A/C Santa Cruz SC6215 1:3000   
 PCNA Santa Cruz sc-56 1:1000   
 Pou5f1 BD Bioscience 611202 1:2000 1:500  
 H3 Abcam 1791 1:10000   
       
       
 
 
 
 
 
Supplemental Experimental Procedures 
 
Constructs 
For site-directed mutagenesis, approximately 25bp long primers containing the 
mutation in the center were used for amplification with Phusion Taq (Finnzymes). The 
PCR reaction was digested with the methylation sensitive restriction enzyme Dpn1 (New 
England BioLabs) to remove the original construct and subsequently used for 
transformation. Successful mutagenesis was confirmed by sequencing. The Cbx2 
truncation constructs were generated by PCR from the Cbx2-EGFP construct. For the 
Cbx4, Cbx7 CD fusion constructs with the Cbx2 AT-hook, a Pst1 site was introduced 
between the CD of Cbx2 and the Cbx2 AT-hook for cloning. The CDs of Cbx4 and Cbx7 
were amplified by PCR. 
 
Cloning, expression and purification of Cbx proteins.  
Cbx2 (9-66), Cbx2 (9-88), Cbx4 (8-65) and Cbx7 (8-62) were obtained as 
described before (Kaustov et al., 2011). Cbx2 (9-66)-A14V, Cbx4 (8-65)-V13A and Cbx7 
(8-62)-V13A  mutations were made by QuickChange II XL site-directed mutagenesis kit 
(Stratagene) and confirmed by complete cDNA sequencing. Proteins for NMR samples 
were prepared in M9-defined medium supplemented with 15N-Ammonium Chloride and 
D-13C6 glucose for uniformly 13C,15N labeled samples or with 13C labeled biosynthetic 
precursors to generate 13C labeled methyl groups of Ile, Leu, Val for ILV labeled samples, 
respectively (Kaustov et al., 2011; Tugarinov et al., 2006).  
 
Mice and Cell Lines 
To produce maternally deficient HP1β mice, Cbx1F/F mice that carried the Zp3-cre 
recombinase transgene were generated. Housing and handling of mice conformed to the 
Swiss Animal Protection Ordinance, chapter 1. 
ESCs were cultured in either DMEM medium with 4.5 g/l glucose (Gibco) 
containing 15% FCS (fetal calf serum, Chemicon), penicillin, streptomycin, 2 mM L-
glutamine, 0.1 mM β-mercaptoethanol, non-essential amino acids and 1mM sodium 
pyruvate (Gibco) or with knockout serum replacement (Invitrogen) in presence of GSK3β 
and MEK1 inhibitors (2i) (CHIR99021, 3µM and PD184352, 0.8µM respectively, Axon 
Medchem). 
Transiently transfected ESCs were seeded after approximately 16h of culture on 
poly-L-lysine coated coverslips, fixed with PFA and mounted in Vectashield containing 
DAPI (Vector). 
Phosphatase Alkaline staining was performed with the Alkaline Phosphatase 
Detection Kit (SCR004, Millipore) following manufacturer’s instructions. 
siRNA knock down in ESCs was performed using Lipofectamine following the 
manufacturer’s instructions (Invitrogen). Briefly, 2.105 cells were transfected with 100 
pmole of siRNA duplexes, and collected 2 days later for subsequent Western blot or IF 
analysis. siRNA were purchased from Microsynth (Switzerland). Sequences are available 
upon request. 
 
Flow Cytometry 
 Transiently transfected cells were harvested with Trypsin, washed in PBS and 
resuspended in 500µL of PBS-0.2%Serum. EGFP expression was analyzed by a flow 
cytometer (FACSCalibur, Beckton Dickinson) using CellQuest software (Beckton 
Dickinson). Plots and quantification of EGFP positive cells were performed with FlowJo 
software (Tree Star). 
 
Collection, in vitro fertilization (IVF), micro-injection and culture of mouse embryos 
Isolation of oocytes, and embryos, generation of mRNA and micro-injection were 
done as previously described (Posfai et al., 2012; Puschendorf et al., 2008).  
Mouse oocytes and embryos were derived from superovulated 5-10 week old 
females according to standard procedures  (Hogan et al., 1994). For IVF, females were 
injected with PMSG (5U, Intervet) and 48h later with hCG (5U, Intervet). M-II oocytes 
were then collected 14h after hCG injection. Sperm was obtained from 10-16 week old 
control males. Capacitation was carried out in human tubular fluid (HTF, Millipore) 
containing 7.5 mg/ml BSA for 2h. IVF was performed in HTF containing 7.5 mg/ml BSA 
(Gibco) for 2h. Zygotes were substaged according to morphology of pronuclei using 
criteria as defined previously (Adenot et al., 1997). In brief, PN0 refers to embryos 
immediately after fertilization and PN5 refers to embryos with large pronuclei located 
centrally within the embryo. For distamycin A treated PN0 zygotes, fertilization was 
performed in HTF containing 7.5 mg/ml BSA supplemented with distamycin A (Sigma, 
#D6135) for 2h.  
For in vitro transcription, the plasmids were linearized and the mMessage 
mMachine T7 kit (Ambion, AM1344) was used. The synthesized mRNA was diluted to the 
optimal concentration using nuclease-free water (Ambion, AM9937). 2-4 pL mRNA 
(100ng/μl) was microinjected into the cytoplasm of in vitro fertilized CD1 zygotes using 
the Eppendorf FemtoJet injector system. Zygotes were then cultured in KSOM medium 
plus amino acids (Chemicon) under a 5% CO2 atmosphere at 37ºC and fixed at late 
zygotic stages (PN5). 
 
Fluorescence Recovery After Photobleaching 
 The Suv39h dn ESCs were transiently transfected using Lipofectamine. For 
imaging, cells were plated on Ibidi plates (Ibidi, Germany), grown 24 hours in ESC 
medium and imaged on a spinning disc confocal setup comprising an Olympus IX81 
(Olympus, Japan) microscope equipped with a Yokogawa CSU-X1 scan head, a 491nm 
laser line, a PlanApo 100x/1.45 TIRFM oil immersion objective, an ASI MS-2000 with Z-
piezo stage, a Semrock Di01-T488/568-13x15x0.5 dichroic, a Semrock FF01-525/40-25 
emission filter and a Cascade II EM-CCD camera (Photometrics). The setup was 
enclosed in a heating box and temperature was set at 37°C and controlled with a “Box” 
element (Life Cell imaging, Basel). The sample was covered with a plate dispensing 
humidified air containing 5% CO2 at a flux rate of 6 l/hour controlled with a “Brick” element 
(Life Cell imaging, Basel). Final pixel size was 94nm. FRAP was performed using a Rapp-
Optoelectronic module equipped with a 473 laser. The results were analyzed using 
ImageJ. 
 
Immunofluorescence Staining 
Before fixation of embryos, the zona pellucida was removed by incubation in acidic 
tyrode for 30 seconds. Embryos were washed twice in FHM, fixed for 15 min in 4% 
paraformaldehyde in PBS (pH 7.4) and permeabilized with 0.2% Triton-X 100 in PBS at 
room temperature (RT). Fixed embryos were blocked at least 4 hours at RT in 0.1% 
Tween-20 in PBS containing 2% BSA and 5% normal goat serum, and were then 
incubated with primary antibodies in blocking solution overnight at 4ºC. For 5mC 
detection, embryos were incubated in 4N HCl for 10 min at room temperature followed by 
neutralization in Tris-HCl, pH 8.0, for 10 min before overnight incubation with the primary 
antibody. Embryos were washed three times for 30 min in 0.1% Tween-20 in PBS 
containing 2% BSA before application of secondary antibodies for 1 hour at RT followed 
by three washing steps for 30 min in 0.1% Tween-20 in PBS containing 2% BSA in the 
dark. Primary antibodies were used in combination with cross-absorbed Alexa 488-, 568-
, or 633-coupled secondary antibodies (Molecular Probes). Embryos were mounted in 
Vectashield containing DAPI (Vector). Mouse ESCs were trypsinized and placed on poly-
L-lysine coated coverslips for 10 min to attach.  Cells were fixed in 2% paraformaldehyde 
in PBS (pH 7.4), permeabilized in 0.1% Triton-X 100 in 0.1% sodium citrate. ESCs were 
blocked for 30 min in 0.1% Tween-20 in PBS containing 2% BSA and 5% normal donkey 
serum at RT and stained as described above. 
 
Microscopy and image analysis 
 Immunofluorescence stainings of embryos were analyzed using the laser scaning 
confocal microscopes LSM510 META (Zeiss; software: LSM Image Browser) and LSM 
700 (Zeiss: software: ZEN). One confocal slice through the maximal radius of each pro- 
nucleus was scanned. The images were projected using ImageJ. Quantification of the 
mean fluorescence intensity of PCH and euchromatin in embryos was performed with 
ImageJ and normalized to background (Figure S3F). Unbiased automatic quantifications 
of fluorescence intensities in ESCs were performed from tiled pictures comprising at least 
64 images taken with a 40X/1.3 oil objective on a Zeiss LSM700 microscope. Images 
were subsequently analyzed with a custom Matlab (MathWorks) script developed in 
house. In a first step, the EGFP (or antibody) positive cells were identified using a k-
means clustering method. Next, the corresponding DAPI channel was classified into PCH 
(high intensity in DAPI), euchromatin (medium intensity in DAPI) and background (low 
intensity in DAPI outside the cell). Mean fluorescence intensity from PCH- and 
euchromatic-identified regions were calculated for both the DAPI and EGFP channel. For 
each labeled cell, the ratio of fluorescence signals at PCH over euchromatic regions was 
calculated for both DAPI and EGFP channels. Numerical data was exported into Excel 
and plotting and statistical analysis of the immunofluorescence data were conducted with 
SigmaPlot (Systat Software). Mann-Whitney U tests were calculated.  
 
Immunoblot Analysis 
 For immunoblot analysis, cells washed with PBS were lysed in Laemmli buffer (for 
histones, acid extraction was performed according to the Abcam protocol). After 
measuring protein quantity by Bradford, equal amounts of protein were resolved by SDS-
PAGE, transferred to a nitrocellulose membrane (Biorad), and probed with a primary 
antibody overnight at 4ºC. Membranes were then incubated with the appropriate HRP-
conjugated secondary antibodies (1:10000, Amersham). The immunoreactive bands 
were detected by chemiluminescence (Thermo Fisher Scientific). 
 
Immunoprecipitation 
 Protein extracts were prepared as followed: 1 volume of cells was resuspended in 
1 volume of low salt buffer (20 mM Hepes at pH 7.9, 10 mM KCl, 0.1% (v/v) NP40 and 
cocktail of protease inhibitors). The lysis mixture was incubated on ice for 10 min. Then, 
1 volume of high salt buffer was added (20 mM Hepes at pH 7.9, 1 M KCl, 6 mM MgCl2, 
20% (v/v) glycerol). DNA was broken with a syringe and needle and the lysis mixture was 
sonicated with a Bioruptor (Diagenode), incubated 30 min at 4 °C and centrifuged for 5 
min at 4 °C. Immunoprecipitation buffer (20mM Hepes at pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2, 0.2% (v/v) Tween20, 10% (v/v) glycerol and cocktail of protease inhibitors) used 
at 2x concentration, was added to the lysis mixture, before pre-clearing with 15μl of 
Dynabeads protein G (Invitrogen) for 1 h at 4 °C with rotation. After collection of the pre-
cleared lysate, 4µg of mouse anti-GFP antibody (Roche) pre-attached to 15µL of 
Dynabeads protein G was added and allowed to precipitate overnight at 4 °C with rotation. 
Beads were collected, washed three times with 1 ml of 1x immunoprecipitation buffer, 
and resuspended in SDS buffer before immunoblot analysis. All buffer were 
supplemented with a cocktail of protease inhibitor (Complete Mini EDTA-free, Roche). 
 
Small-scale biochemical fractionation 
One day after transfection of ESCs with Cbx2-EGFP constructs, 10x106 cells were 
collected and subcellular fractions were then prepared and analyzed by Western blot as 
previously described (Julien and Herr, 2004).  
 
Chromatin immunoprecipitation 
 ChIP-qPCR from ESCs was performed according to previously described 
protocols with modifications (Mohn et al., 2008; Tardat et al., 2010). Cells were collected, 
washed in PBS and were cross-linked in PBS containing 1% formaldehyde for 10 min at 
room temperature. The Cross-linking reaction was stopped by addition of glycine 
(125mM) for 5 min at RT. Cells were then washed twice with cold PBS. Pellets were 
resuspended in 15 mL buffer 1 (10 mM Tris (pH 8.0), 10 mM EDTA, 0.5 mM EGTA, 0.25% 
Triton X-100) and twice in 15 mL buffer 2 (10 mM Tris (pH 8.0), 1 mM EDTA, 0.5 mM 
EGTA, 200 mM NaCl). Then cells were lysed in 1 mL lysis buffer (50 mM HEPES/KOH 
(pH 7.5), 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% DOC, 0.1% SDS, protease 
inhibitors) and incubated on ice for at least 1h. DNA was sheared with first a 10 sec pulse 
using a Branson sonicator (amplitude 70%), then samples were aliquoted in 1.5mL 
Eppendorf tubes containing 250µL of lysate each prior to sonication with a Bioruptor 
(Diagenode) for 25-30 cycles. DNA fragments length (between 200-600bp on average) 
was checked on agarose gel stained with ethidium bromide. For the immunoprecipitation, 
we incubated between 30-50µg of chromatin overnight at 4 °C with 3-5µg of indicated 
antibodies (Table S1) pre-attached to 15µL of Dynabead protein G (Invitrogen). Beads 
were washed twice with 1 mL lysis buffer, once with 1 mL DOC buffer (10 mM Tris (pH 
8.0), 0.25 M LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA), once with 1mL TE 
buffer and bound chromatin was eluted in 1% SDS/0.1 M NaHCO3. After RNase A 
treatment followed by proteinase K digestion, cross-linking was reversed by overnight 
incubation at 65 °C. DNA was purified with the MinElute PCR Purification Kit according 
to the manufacturer's instructions (Qiagen). ChIP experiments were performed at least 
three times from independent chromatin preparations, and quantitative PCR analyses of 
ChIP DNAs were performed in triplicate using a SYBR Green quantitative PCR kit 
(Invitrogen) and a ABI 7500 Fast or a ABI StepOnePlus apparatus (Applied Biosystems), 
under conditions standardized for each primer set (primers are available upon request). 
The amount of DNA in ChIP samples was extrapolated from standard curve analysis of 
chromatin DNA before immunoprecipitation (input chromatin). 
 
Preparation of NCP with H3 methylated histone analog.  
Methylated H3Kc27me3 histone was prepared as described previously (Simon et 
al., 2007). The 601-DNA (‘Widom’ DNA) was obtained from 32X plasmid which contains 
32 repeats of the 601-DNA sequence which were cleaved using ECORv and then used 
for nucleosome reconstitution using salt-gradient dialysis method as described 
previously) (Dyer et al., 2004).  
 
Fluorescence Polarization 
Chromodomains of Cbx2 (9-66), Cbx4 (8-65) and Cbx7 (8-62) were amplified by 
PCR from the Mammalian Gene Collection clones and were subcloned into a modified 
pET28a-LIC vector. The recombinant proteins and their corresponding mutants were 
overexpressed as N-terminal His6-tagged proteins at RT using E. coli BL21 (DE3) Codon 
plus RIL (Stratagene) as a host organism. These expressed proteins were purified by 
Talon (BD) affinity chromatography under native conditions and eluted with buffer 
containing 500 mM Imidazole followed by size exclusion chromatography using a HiLoad 
26/60 Superdex-75 column (GE Healthcare). The proteins were monomeric in solution as 
determined by size exclusion chromatography. The final samples were prepared in buffer 
containing 20 mM Tris (pH 8), 250 mM NaCl, 1mM DTT, 1mM TCEP, 1 mM Benzamidine, 
and 0.5 mM PMSF. 
The buffer used in the binding assays contained 20 mM Tris pH 8.0, 250 mM NaCl, 
1 mM DTT, 5 mM β-mercaptoethanol, 1 mM Benzamidine, 1 mM PMSF, and 0.01% 
Tween-20. Fluorescence polarization assays were performed in 384 well plates using 
Synergy 2 microplate reader (BioTek, Vermont, USA). To determine Kd values, the data 
were fit to a hyperbolic function using SigmaPlot software (Systat Software, Inc., CA, 
USA). 
 
NMR spectroscopy and data analysis 
The sequence-specific assignments of backbone and side chain resonances of 
human Cbx2CD-AT were assigned using the ABACUS approach from peak lists derived 
manually from peak picked spectra using NMR data collected at high resolution from non-
linearly sampled spectra and processed using multidimensional decomposition 
(Gutmanas et al., 2002; Orekhov et al., 2003). We obtained assignments for all Ile, Leu 
and Val methyl groups of Cbx2CD-AT  (2 Ile, 3 Val and 9 Leu) which were then used for 
chemical shift mapping for a U-[15N,2H]-labeled Cbx2CD-AT  sample with Ile, Leu and Val 
selectively labeled with 13C. Chemical shift mapping of Cbx2CD-AT was measured from the 
[15N,1H] and [13C,1H] TROSY spectra of U-[15N,1H] or U-[15N,2H],Ileδ1-[13CH3], Leu,Val-
[13CH3,12CD3]-labeled Cbx2CD-AT, respectively at protein concentrations ranging from 
0.15mM-0.45mM,  alone and with aliquots of [2H]-H3K27cme3-NCP (1:1, 1:2, and 1:3 
molar ratios) or unlabeled H3K27me3 peptide (residues 19-33; 1:1, 1:3 and 1:6 molar 
ratios) until no further changes in chemical shifts were detected. The TROSY and HSQC 
spectra were recorded at 250C in 90/10% H2O/D2O with 20 mM TRIS pH 7.7, 150 mM 
NaCl, 1mM benzamidine, 0.5mM phenylmethylsulfonyl fluoride, 3mM β-mercaptoethanol. 
NMR experiments were performed at 293K on 600 and 800 MHz Bruker Avance 
spectrometers equipped with cryoprobes. Composite chemical shift perturbation (CSP) 
values were calculated using the equations Δ(δ1H-15N) = [(Δδ1H)2 + (Δδ15N/5)2]1/2 and 
Δ(δ1H-13C) = [(Δδ1H)2 + (Δδ13C/4)2]1/2. The data were processed with NMRPipe (Delaglio 
et al., 1995) and analyzed with NMRView and Sparky software (Goddard et al., 2006). 
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